{"id":12675,"date":"2025-11-10T19:46:46","date_gmt":"2025-11-10T19:46:46","guid":{"rendered":"https:\/\/fundinguno.com\/?p=12675"},"modified":"2025-11-10T19:46:47","modified_gmt":"2025-11-10T19:46:47","slug":"regeneron-pharmaceuticals-inc-regn-discusses-factor-xi-development-program-and-clinical-data-in-hematology-pipeline-transcript","status":"publish","type":"post","link":"https:\/\/fundinguno.com\/?p=12675","title":{"rendered":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript"},"content":{"rendered":"<div seq=\"0\">\n<p class=\"transcript-presentation-section-title\"><span><strong>Operator<\/strong><\/span><\/p>\n<p>Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today&#8217;s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.<\/p>\n<\/p><\/div>\n<div seq=\"1\">\n<p class=\"transcript-presentation-section-title\"><span><strong>Ryan Crowe<\/strong><\/span><br \/><span><i>Senior Vice President of Investor Relations &amp; Strategic Analysis<\/i><\/span><\/p>\n<p>Thank you, Shannon. Good morning, and welcome to the inaugural Regeneron Roundtable Investor Event, the first in a series of presentations that will spotlight key opportunities across our pipeline.<\/p>\n<p>Today, we will focus on our Factor XI development program, which began initial Phase III studies earlier this year. Today&#8217;s roundtable features key R&amp;D leaders from Regeneron, including Dr. George Yancopoulos, Board Co-Chair, President and Chief Scientific Officer; Dr. Andres Sirulnik, Senior Vice President and Clinical Development Unit Head, Hematology; and David &#8212; Dr. David Gutstein, Vice President and Global Program Head, Hematology.<\/p>\n<p>Before we begin, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject<\/p>\n<\/p><\/div>\n<p>Read the full article <a href=\"https:\/\/seekingalpha.com\/article\/4841324-regeneron-pharmaceuticals-inc-regn-discusses-factor-xi-development-program-and-clinical-data?source=feed_all_articles\" target=\"_blank\" rel=\"noopener\" rel=\"nofollow\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today&#8217;s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin. Ryan CroweSenior Vice President of Investor Relations &amp; Strategic Analysis Thank you, Shannon. Good morning, and welcome to the inaugural Regeneron Roundtable Investor Event, the first in a series of presentations that will spotlight key opportunities across our pipeline. Today, we will focus on<\/p>\n","protected":false},"author":1,"featured_media":525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[],"class_list":["post-12675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | FundingUno<\/title>\n<meta name=\"description\" content=\"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundinguno.com\/?p=12675\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | FundingUno\" \/>\n<meta property=\"og:description\" content=\"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundinguno.com\/?p=12675\" \/>\n<meta property=\"og:site_name\" content=\"FundingUno\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T19:46:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T19:46:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundinguno.com\/wp-content\/uploads\/2023\/10\/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fundinguno.com\/?p=12675\",\"url\":\"https:\/\/fundinguno.com\/?p=12675\",\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | FundingUno\",\"isPartOf\":{\"@id\":\"https:\/\/fundinguno.com\/#website\"},\"datePublished\":\"2025-11-10T19:46:46+00:00\",\"dateModified\":\"2025-11-10T19:46:47+00:00\",\"author\":{\"@id\":\"https:\/\/fundinguno.com\/#\/schema\/person\/98b5a7e1b2725895bfea68182828f468\"},\"description\":\"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for\",\"breadcrumb\":{\"@id\":\"https:\/\/fundinguno.com\/?p=12675#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fundinguno.com\/?p=12675\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fundinguno.com\/?p=12675#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fundinguno.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fundinguno.com\/#website\",\"url\":\"https:\/\/fundinguno.com\/\",\"name\":\"FinMarkPros\",\"description\":\"Latest Finance News and Updates\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fundinguno.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fundinguno.com\/#\/schema\/person\/98b5a7e1b2725895bfea68182828f468\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fundinguno.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e8b130588e3e0973c44e4fcddcd4587da79e3ed9fe4aba5ba76d09c3da7fdee3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e8b130588e3e0973c44e4fcddcd4587da79e3ed9fe4aba5ba76d09c3da7fdee3?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fundinguno.com\"],\"url\":\"https:\/\/fundinguno.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | FundingUno","description":"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundinguno.com\/?p=12675","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | FundingUno","og_description":"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for","og_url":"https:\/\/fundinguno.com\/?p=12675","og_site_name":"FundingUno","article_published_time":"2025-11-10T19:46:46+00:00","article_modified_time":"2025-11-10T19:46:47+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/fundinguno.com\/wp-content\/uploads\/2023\/10\/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fundinguno.com\/?p=12675","url":"https:\/\/fundinguno.com\/?p=12675","name":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | FundingUno","isPartOf":{"@id":"https:\/\/fundinguno.com\/#website"},"datePublished":"2025-11-10T19:46:46+00:00","dateModified":"2025-11-10T19:46:47+00:00","author":{"@id":"https:\/\/fundinguno.com\/#\/schema\/person\/98b5a7e1b2725895bfea68182828f468"},"description":"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for","breadcrumb":{"@id":"https:\/\/fundinguno.com\/?p=12675#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundinguno.com\/?p=12675"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fundinguno.com\/?p=12675#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fundinguno.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript"}]},{"@type":"WebSite","@id":"https:\/\/fundinguno.com\/#website","url":"https:\/\/fundinguno.com\/","name":"FinMarkPros","description":"Latest Finance News and Updates","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fundinguno.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fundinguno.com\/#\/schema\/person\/98b5a7e1b2725895bfea68182828f468","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fundinguno.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e8b130588e3e0973c44e4fcddcd4587da79e3ed9fe4aba5ba76d09c3da7fdee3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e8b130588e3e0973c44e4fcddcd4587da79e3ed9fe4aba5ba76d09c3da7fdee3?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/fundinguno.com"],"url":"https:\/\/fundinguno.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/posts\/12675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fundinguno.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12675"}],"version-history":[{"count":1,"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/posts\/12675\/revisions"}],"predecessor-version":[{"id":12676,"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/posts\/12675\/revisions\/12676"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fundinguno.com\/index.php?rest_route=\/wp\/v2\/media\/525"}],"wp:attachment":[{"href":"https:\/\/fundinguno.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fundinguno.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fundinguno.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}